Search articles in COVID-19

Filter Articles

Open filters

Sections

Found 106 articles

The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response
- 8 Apr 2020
- PharmiWeb Editor
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation, a nonprofit charitable foundation, commits to make donations totaling $5 million in 2020 to support global COVID-19 relief efforts, including doubling its match for employees’ charitable donations to eligible organizations responding to the COVID-19 pandemic.
COVID-19: How lockdown could affect our long term health
- 8 Apr 2020
- PharmiWeb Editor
Researchers at the University of East Anglia are launching a new project to track the health of the nation during lockdown, and they are looking for volunteers to take part.
CROMSOURCE Announces Launch of COVID-19 Clinical Trial
- 7 Apr 2020
- PharmiWeb Editor
CROMSOURCE, an international contract research organization (CRO) with its global headquarters in Verona, Italy, has announced that it has initiated its first COVID-19 trial on behalf of a European pharmaceutical company.
PharmiWeb Advertising NHS COVID-19 Jobs for Free.
- 7 Apr 2020
- PharmiWeb Editor
At this challenging time, we at PharmiWeb are pleased to step forward and do our small part by helping the NHS recruit urgently needed staff for the battle against COVID-19.
ZEGAMI BUILDS NEW TECH PLATFORM TO ANALYSE COVID-19 X-RAYS TO HELP SPEED UP DIAGNOSIS AND POTENTIALLY LEAD TO MORE EFFECTIVE TREATMENTS
- 7 Apr 2020
- PharmiWeb Editor
Zegami, the Oxford University data visualisation spin-out, has developed a new machine learning model using x-rays of Covid-19 infected lungs, artificial intelligence techniques and data visualisation tools that could help medical professionals identify Coronavirus cases more effectively, but also potentially help provide a better idea of potential outcomes for patients, and even lead to more effective treatments.
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
- 7 Apr 2020
- PharmiWeb Editor
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.
Independent Site Management Organisation Panthera prepares for COVID-19
- 7 Apr 2020
- PharmiWeb Editor
The safety of clinical trial patients and staff is paramount. We are working with our clients in pharma and CROs to assess each trial to see if it needs to be suspended, delayed or if it can carry on in a way that is safe both for the clinicians and participants
APEIRON Biologics Initiates Phase II Clinical Trial of APN01 for Treatment of COVID-19
- 2 Apr 2020
- PharmiWeb Editor
APEIRON Biologics AG today announced that it has received regulatory approvals in Austria, Germany and Denmark to initiate a Phase II clinical trial of APN01 to treat COVID-19
EUSA PHARMA AND PAPA GIOVANNI XXIII HOSPITAL, ITALY, PROVIDE INTERIM ANALYSIS DATA FOR SILTUXIMAB-TREATED COVID-19 PATIENTS FROM THE SISCO STUDY
- 1 Apr 2020
- PharmiWeb Editor
EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced initial preliminary findings from the Papa Giovanni XXIII Hospital sponsored SISCO (Siltuximab In Serious COVID-19) Study,1 based on a pre-planned data analysis on 24 March 2020.
Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19
- 1 Apr 2020
- PharmiWeb Editor
Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19
Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
- 1 Apr 2020
- PharmiWeb Editor
Kiniksa Pharmaceuticals, Ltd., today announced early evidence of treatment response with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in a treatment protocol in patients with severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation.
GILEAD SCIENCES ANNOUNCES TWO PHASE 3 RANDOMISED STUDIES TO EVALUATE THE SAFETY AND ANTIVIRAL ACTIVITY OF REMDESIVIR (GS-5734™) IN PARTICIPANTS WITH MODERATE TO SEVERE COVID-19
- 1 Apr 2020
- PharmiWeb Editor
Gilead Sciences announced today that the company has initiated two phase 3 randomised studies to evaluate the safety and efficacy of its investigational treatment remdesivir in patients with moderate to severe COVID-19 (coronavirus).
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19
- 31 Mar 2020
- PharmiWeb Editor
Johnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020
Coronavirus pandemic pushes pharma sales reps deeper into virtual space, says GlobalData
- 31 Mar 2020
- PharmiWeb Editor
As the novel coronavirus (COVID-19) pandemic continues to spread globally, virtual platforms will experience an extra boost after already having a transformational impact on the entire healthcare landscape even before the outbreak, says GlobalData, a leading data and analytics company.
LifeArc launches £10 million research fund to address the challenges of COVID-19
- 26 Mar 2020
- PharmiWeb Editor
LifeArc, a UK-based medical research charity, has created a £10 million fund to support research to accelerate the development and testing of therapeutics that can be rapidly deployed to treat the symptoms of COVID-19. The charity is seeking applications from academics or companies that have molecules that could be repurposed or repositioned for use in COVID-19 patients
AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19
- 26 Mar 2020
- PharmiWeb Editor
AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZeneca has partnered with the World Economic Forum’s COVID Action Platform, created with the support of the World Health Organisation, to identify countries in greatest need. Italy will receive the first shipments this week with other countries to follow.
Babylon launches COVID-19 Care Assistant for the Coronavirus pandemic
- 26 Mar 2020
- PharmiWeb Editor
Babylon’s new COVID-19 Care Assistant can be used 24/7 and combines continually-updated information, triage, live chat, symptom tracking, virtual consultation and referrals. This approach means we can greatly increase our ability to simultaneously give help to people with questions or concerns, and for whom treatment involves self-isolation, whilst still giving detailed and thorough care to people who need more intensive attention.
Prioritising NHS workers for coronavirus testing is crucial
- 26 Mar 2020
Responding to the news that the 3.5 million antibody tests will prioritise key workers including NHS staff, Layla McCay, director of the NHS Confederation....
Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19
- 26 Mar 2020
- PharmiWeb Editor
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has identified multiple human monoclonal antibody (mAb) development candidates that neutralize SARS-CoV-2, the virus responsible for COVID-19.
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
- 26 Mar 2020
- PharmiWeb Editor
Grifols today announces that it has entered into a formal collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies to collect plasma from convalescent COVID-19 patients...